PHAT - Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals Inc Logo

PHAT - Phathom Pharmaceuticals Inc

https://www.phathompharma.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing
GlobeNewswire • 3 weeks, 5 days ago • score: 0.32
FLORHAM PARK, N.J., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but ...
Bullish
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® ( vonoprazan ) Tablets Through May 3, 2032 - Phathom Pharmaceuticals ( NASDAQ:PHAT )
Benzinga • 2 months, 4 weeks ago • score: 0.39
FLORHAM PARK, N.J., June 16, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. PHAT, a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ( GI ) diseases, today announced that the U.S.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.

52W High
$19.71
52W Low
$2.21
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.44
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-2.20
EV/Revenue (<3 favorable)
8.17
P/S (TTM) (<3 favorable)
7.68
P/B (<3 favorable)
25.37
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
4.20%
Institutions (25–75% balanced)
84.02%
Shares Outstanding
70,944,000
Float
51,191,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
114,039,000
Gross Profit (TTM)
99,106,000
EPS (TTM)
-4.67
Profit Margin (>10% good)
-2.90%
Operating Margin (TTM) (higher better)
-1.52%
ROE (TTM) (>15% strong)
-34.89%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
4.39
Momentum
Bearish momentum
Value
0.7228
Previous
0.8167
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025